

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/521,040 Confirmation No. : 6630  
Applicants : Herman Jan Tijmen Coelingh Bennink et al.  
Filed : August 16, 2005  
Title : PHARMACEUTICAL COMPOSITION COMPRISING  
ESTETROL DERIVATIVES FOR USE IN CANCER  
THERAPY  
Group Art Unit : 1616  
Examiner : Mei-Ping Chui  
Customer No. : 28289

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to the requirements of 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby submit this Information Disclosure Statement (“IDS”). Pursuant to 37 C.F.R. § 1.98 (a), a legible copy of each reference cited in this IDS is provided herein. The cited United States patents and/or United States published patent applications are not enclosed pursuant to the waiver of this requirement under 37 C.F.R. § 1.98(a)(2)(i). For any reference not in the English language, all of the translations or partial translations within the possession, custody or control of, or readily available to individuals designed under 37 C.F.R. § 1.56(c) for the instant application have been enclosed pursuant to 37 C.F.R. § 1.98 (a)(3)(ii).

In this IDS, Applicants also disclose Office Actions from United States patent applications assigned to the assignee of this application that are directed to related

I hereby certify that this correspondence is being electronically submitted to the United States Patent and Trademark Office on October 22, 2009.

  
\_\_\_\_\_  
10/22/2009  
Date  
\_\_\_\_\_  
Signature  
\_\_\_\_\_  
Mary Ann Mulvihill  
(Name of Person Submitting Paper)

technology. These office actions can be found in the following patent applications:

U.S. Pat. App. No.	Examiner
10/478,262	Hui
10/478,264	Hui
10/478,357	Hui
10/478,365	Chui
10/495,707	Sullivan
10/517,509	Jean-Louis
10/517,686	Chui
10/521,040	Chui


Additionally, Applicants wish to disclose that United State Patent Application No. 12/522,315 is a related patent application where no action has yet been issued by the United States Patent and Trademark Office.

This Information Disclosure Statement is being submitted together with a fee of \$180.00 pursuant to 37 C.F.R. §§ 1.97 (c) and 1.17 (p) as it is being submitted before the mailing date of a final Office Action or a Notice of Allowance under § 1.311. The Director for the United States Patent and Trademark Office is hereby authorized to charge any fees that may be required to Deposit Account No. 23-0650. Please refund any overpayment to Deposit Account No. 23-0650.

The Applicants submit that they have complied with the requirements set forth in 37 C.F.R. §§1.56, 1.97 and 1.98, and therefore respectfully request that this Information Disclosure Statement and the cited references be considered and made of record.

Respectfully submitted,

THE WEBB LAW FIRM

By   
William H. Logsdon  
Registration No. 22,132  
Attorney for Applicants  
436 Seventh Avenue  
700 Koppers Building  
Pittsburgh, PA 15219  
Telephone: (412) 471-8815  
Facsimile: (412) 471-4094  
E-mail: webblaw@webblaw.com